Key result
Among rivaroxaban users with nonvalvular atrial fibrillation, patients with diabetes mellitus had a higher incidence of major bleeding than those without.
Why the study?
Does the presence of diabetes mellitus increase the incidence of major bleeding in patients with nonvalvular atrial fibrillation treated with rivaroxaban?
Observational (n=44,793)
Yes
Does the presence of diabetes mellitus increase the incidence of major bleeding in patients with nonvalvular atrial fibrillation treated with rivaroxaban?
In a real-world cohort of patients with nonvalvular atrial fibrillation taking rivaroxaban, the presence of diabetes mellitus was associated with a significantly higher incidence of major bleeding.
Answers are grounded in this paper and cite their sources.
DM may raise major bleeding risk on rivaroxaban in NVAF; leaves open confirmation and therapy adjustment in prospective trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Peacock et al. (2016) conducted an observational in Nonvalvular Atrial Fibrillation (NVAF) (n=44,793). Rivaroxaban in patients with Diabetes Mellitus vs. Rivaroxaban in patients without Diabetes Mellitus was evaluated on Incidence of major bleeding per 100 person-years. Among rivaroxaban users with nonvalvular atrial fibrillation, patients with diabetes mellitus had a higher incidence of major bleeding than those without.
Synapse has enriched 10 related papers. Consider them for comparative context: